Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

North West Digital Clinical Trial Recruitment Company Secures Six Figure Investment

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
UK Company has secured an investment of more than £250,000.

A UK Company which offers an innovative solution to recruit and retain global participants for medicine clinical trials has secured an investment of more than £250,000 from a group of investors.

Tomorrows Medicines Limited, based at Daresbury Sci-Tech, Cheshire has secured £100,500 from The North West Fund for Biomedical, managed by SPARK Impact, another £100,500 from private investors and £50,000 from the Technology Strategy Board.

Tomorrows Medicines has developed an interactive web platform called YourTreatmentChoices.com where patients can find and join local clinical trials.

It also services global pharmaceutical, biotech, diagnostic, academic and other research organization study teams in recruiting and retaining trial participants.

Delays in patient recruitment can lead to a delay in bringing new medicines to market. In the UK, issues with patient recruitment mean that 40 per cent of trials do not complete at all.

The funding will be used by Tomorrow Medicines to commercialize the YourTreatmentChoices.com platform and service. So far, the website has helped patients in 78 countries to find approved clinical trials in their local area.

Dr Clare Nolan, CEO of Tomorrows Medicines Limited said: “We are delighted to receive the funding from the three parties and to receive recognition that the company provides an important service offering. It will enable us to provide a fully-supported service to global pharmaceutical, biotech and diagnostic companies looking to accelerate patient recruitment across all clinical areas. The clinical trial recruitment process is critical for the discovery of much-needed medical treatments and we can now make this process simpler, faster and more accessible.”

Dr Penny Attridge, senior investment director at SPARK Impact and manager of The North West Fund for Biomedical, said: “From day one we could see the potential in Tomorrows Medicines’ novel, interactive platform for patient recruitment and retention services. Clinical research offers exciting drug discovery opportunities and we hope the investments will make a real difference to continue to grow the company.”

Melanie Yeomans, corporate finance partner at the Manchester office of law firm Ward Hadaway, who advised SPARK on the investment, said: "We were delighted to advise SPARK on its investment in Tomorrows Medicines.

"The company's processes for the matching of patients to relevant medical trials have clearly exciting and far-reaching potential in both the development of new drugs and the successful treatment of patients for whom existing drug therapies have proved unsuccessful."

Tomorrow Medicines Limited is The North West Fund for Biomedical’s 60th investment to date and the 40th company to be supported by the Fund.

The North West Fund for Biomedical is part of the wider North West Fund, financed jointly by the European Regional Development Fund and the European Investment Bank.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!